標(biāo) 志 性 成 果 |
楊利軍,,教授,,博士生導(dǎo)師,博士后指導(dǎo)教師,山西省學(xué)術(shù)技術(shù)帶頭人,,山西省中青年拔尖創(chuàng)新人才,山西省高校優(yōu)秀青年學(xué)術(shù)帶頭人?,F(xiàn)擔(dān)任山西醫(yī)科大學(xué)科學(xué)技術(shù)部部長(zhǎng),、醫(yī)學(xué)科學(xué)院常務(wù)副院長(zhǎng),兼任山西省醫(yī)學(xué)會(huì)科研管理分會(huì)候任主任委員,、中國(guó)高等教育學(xué)會(huì)科技管理研究分會(huì)理事,、山西省專利保護(hù)協(xié)會(huì)常務(wù)理事,山西省藥學(xué)會(huì)應(yīng)用藥理學(xué)專業(yè)委員會(huì)副主任委員等職務(wù),。主要研究方向是小分子多肽靶向藥物研究和腫瘤免疫分子生物學(xué)研究,。先后承擔(dān)國(guó)家十二五重大新藥創(chuàng)制課題、國(guó)家自然科學(xué)基金等多項(xiàng)國(guó)家級(jí)科研項(xiàng)目,,主持山西省重點(diǎn)研發(fā)計(jì)劃重點(diǎn)項(xiàng)目等省部級(jí)課題10余項(xiàng),,獲省級(jí)科技獎(jiǎng)勵(lì)10余項(xiàng),發(fā)表各類學(xué)術(shù)論文 60 多篇,。 1. Qi Zhao, Xing Lv, Yanqun Dong, Hanyu Hong, Yanbo Zheng, Lijun Yang*, Jianhua Gong*. IMB5036 overcomes resistance to multiple chemotherapeutic drugs in human cancer cells through pyroptosis by targeting the KH-type splicing regulatory protein. Life Sciences, 2023, 328:121941 2. Qi Zhao, Yanbo Zheng, Xing Lv, Jianhua Gong,Liju Yang*.IMB5036 inhibits human pancreati c cancer growth primarily through activating necroptosis, Basic Clin Pharmacol Toxicol, 2021, 130 (3): 375-384 3. Chen Junjun, Dai Jie, Kang Zhiming, Yang Ting, Zhao Qi, Zheng Jinxiu, Zhang Xinxin, Zhang Jisheng, Xu Jun, Sun Gongqin,Yang Lijun*,Yang Tao*. A combinatorial strategy for ov ercoming primary and acquired resistance of MEK inhibition in colorectal cancer, Experimental Cell Research, 2020, 393(1): 1-10 4. Lijun Yang, Yutao Wang, Haifeng Zheng,Dong Zhang, Xiangwei Wu, Gongqin Sun, Tao Yang*. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-de pendent mechanisms, Journal of Chemotherapy, 2017, 29(3): 179-188 5. Lijun Yang, Litao Zhang, Lihong Yan, Haifeng Zheng, Peifen Lu, Junjun Chen, Jie Dai, Haibiao Sun, Yong Xu,Tao Yang*. Stability assessment of a new antithrombotic small peptide, Arg-Gly- Asp-Trp-Arg (RGDWR), and its derivative, Biotechnology Letters, 2017, 39(8): 1183-1190 |